Faced in the past with increased pressure to reduce costs, drug manufacturers embraced just-in-time (JIT) or lean manufacturing supply chain inventory systems. This resulted in companies buying smaller quantities of raw materials from suppliers and reducing the number of materials in inventory, leading to an increased return on investment (ROI) among other benefits.

As the COVID-19 outbreak became a pandemic and countries began closing their borders and restricting trade and exports, there are those in pharma who wish they had larger inventories of raw materials or active pharmaceutical ingredients (APIs) to sustain their manufacturing processes for a longer period of time.

The full impact of the pandemic has yet to be felt, and the intricate and proprietary nature of pharma supply chains prevents an overall industry analysis. Considering the current reality, is the JIT model now dead or dying in the pharma industry?

Is Just-In-Time Dead?

This topic was one of several addressed at an ISPE-sponsored webinar, “COVID-19: Pharma Supply Chain Security & Robustness During Global Pandemic,” held on April 2, 2020.

Verta Life Sciences Managing Partner Nick Davies, a moderator of the session, asked the panel a simple question an audience member submitted, “Is just-in-time dead?”

Gilead Sciences Corporate Operations Senior VP Joydeep Ganguly began his remarks by discussing supply chains in the pharma industry in general.

He commented on the importance of being agile, and how the JIT philosophy around low inventory levels and pharmaceutical efficiency has resulted in some interesting concerns “when you cannot get your workforce into a facility or a site.”

What I think we can learn from this right now is our ability to react to the next crisis that will occur will be less a function of the dominant supply chain model we have chosen, but truly will be a function of our culture of agility and our culture of innovation and our culture of driving change and accepting change and reacting appropriately

Ganguly also pointed out that, “supply chains that have been heavily reliant on large inventory levels, which were touted as being super inefficient in the past, are the ones that are now being touted as super resilient.”

The pandemic and its impact on pharma, he said, “has taught us that we really cannot be arrogant about having one model that drives a pervasive view on how we structure our supply chain.”

“What I think we can learn from this right now,” Ganguly continued, “is our ability to react to the next crisis that will occur will be less a function of the dominant supply chain model we have chosen, but truly will be a function of our culture of agility and our culture of innovation and our culture of driving change and accepting change and reacting appropriately.”

Regarding the JIT question, he said, “I don’t think just-in-time is dead. I do believe we will get over this crisis and that we will go back to where some of the just-in-time principles have led to an unprecedented value that we have given back not just to the shareholder but in terms of innovative therapies for patients.”

[NOTE: Stay focused on your company’s recent changes and let Govzilla PRO do the monitoring for you.  Sign up for a free account to see how it will help your company.]

Get Started with Redica for Free

Where Inventory is Kept Will Be Important

North Carolina State University Poole College of Business Supply Chain Resource Cooperative Executive Director Robert Handfield—who is currently writing a book on next-generation supply chains—agreed.

“I don’t believe JIT is dead. I think this issue is not so much keeping less inventory, but where we keep the inventory and how we develop agile supply chains. I think the velocity of material flow is critical while looking at the security of supply.”

Handfield pointed out that in other industries—for example in the automotive industry—suppliers tend to be local. “There is a reason for that. It is not just for JIT. It is also around communication and the velocity of material movement. I think we are really going to start to look at how we drive greater collaboration—and not just make a decision based on the lowest price. We need to think about the overall supply.”

He also predicted that people would start rethinking keeping larger inventories. “And I think organizations also need to rethink their business continuity planning.”

Handfield commented that “it is difficult before a pandemic to ask what the ROI is of keeping a bunch of material in a stockpile. That becomes very clear when you have an event like this.”

He also commented that he does not believe this is an isolated event. “I have read where these kinds of COVID viruses could recur, and there may even be a vaccine that becomes part of the ecosystem as well in conjunction with the flu vaccine. I think this may be a more regular event that we need to be prepared for. And I think organizations are going to rethink this going forward.”

What is the ROI for Risk Management Processes?

Regarding organizational responses and learning, Ganguly commented, “one big takeaway for us…is the ROI for risk management processes” and the importance of performing risk planning, management, and governance processes. He maintained that some serious risk scenarios are “now manifesting themselves in reality. The worst time to find out your readiness and preparedness for a crisis is during a crisis.”

Vetter Pharmaceuticals Supply Chain and Customer Project Management VP Timo Usinger also addressed supply chain risk management. He commented on how difficult it can be to get support for performing a supply chain risk management evaluation.

“If you want to have a discussion or start a project on this topic, nobody from management or from your stakeholders is clapping his hands. In the event that something happens, like now, everybody is talking about this. I hope that the sustainability of the supply chain or supplier risk management will be increased in the future.”

Buffer stocks cost money…. But what does it cost if there is no stock available and you need to shut down production? If there is no free capacity and you have these kinds of events, how do we react? Maybe we would lose more money

Regarding inventory costs, Usinger commented, “Buffer stocks cost money…. But what does it cost if there is no stock available and you need to shut down production? If there is no free capacity and you have these kinds of events, how do we react? Maybe we would lose more money.”

He expressed his hope that the lessons learned from the impact of the COVID-19 pandemic on pharma supply chains would be long-lasting. What he does not want to see, he said, is “four years later everybody asking again what the logistics cost per unit area and asking to bring them down and having the just-in-time principle in place again.”

In conclusion, Usinger commented, “just-in-time is not dead, but maybe a little bit more dead than yesterday.”

In addition to Ganguly, Handfield, and Usinger, also on the panel were Lonza Pharma and Biotech Supply Chain Planning and Program Management Head Christian Morello and United Parcel Service (UPS) Healthcare Sales Managing Director Jen Trone, who weighed in on other topics during the webinar.

[NOTE: Stay focused on your company’s recent changes and let Govzilla PRO do the monitoring for you. Sign up for a free account to see how it will help your company.]

Get Started with Redica for Free

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

June 29, 1:30 p.m. EST

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.